Q-omics provides the consensus-scored FIGNL2-DT profile across patient tissues and cancer cell-line models. FIGNL2-DT expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, FIGNL2-DT is differentially expressed in 9, with the highest sampling consensus in KICH. Additionally, FIGNL2-DT RNA expression shows 15,553 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight UCEC, KICH, and TGCT as cancer lineages where FIGNL2-DT shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FIGNL2-DT — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FIGNL2-DT survival associations across molecular data types. FIGNL2-DT RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FIGNL2-DT RNA expression–survival associations across cancer types. High FIGNL2-DT expression shows unfavorable associations in UCEC, MESO, UVM, STAD and KIRC, but favorable associations in KIRP. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for FIGNL2-DT RNA expression.
This table summarizes FIGNL2-DT tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for FIGNL2-DT. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FIGNL2-DT shows lower tumor expression in KICH, BRCA and LUSC and higher tumor expression in THCA, LIHC and KIRC. The KICH box plot shows higher FIGNL2-DT RNA expression in normal versus tumor tissue (log2 FC = −2.468, t-test p < 0.001).
This table shows molecular features associated with FIGNL2-DT in patient tissues and cancer cell lines. In patient samples, FIGNL2-DT shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
